Free Trial
NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

Werewolf Therapeutics logo
$1.08 -0.06 (-5.26%)
Closing price 04:00 PM Eastern
Extended Trading
$1.07 -0.01 (-0.83%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Key Stats

Today's Range
$1.02
$1.19
50-Day Range
$0.63
$1.17
52-Week Range
$0.60
$5.73
Volume
981,108 shs
Average Volume
422,184 shs
Market Capitalization
$48.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33
Consensus Rating
Buy

Company Overview

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Werewolf Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

HOWL MarketRank™: 

Werewolf Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 359th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Werewolf Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Werewolf Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Werewolf Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Werewolf Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Werewolf Therapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.49% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently decreased by 4.87%, indicating that investor sentiment is improving.
  • Dividend Yield

    Werewolf Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Werewolf Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.49% of the float of Werewolf Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Werewolf Therapeutics has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Werewolf Therapeutics has recently decreased by 4.87%, indicating that investor sentiment is improving.
  • News Sentiment

    Werewolf Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Werewolf Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for HOWL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Werewolf Therapeutics insiders have bought 9,348.08% more of their company's stock than they have sold. Specifically, they have bought $435,273.00 in company stock and sold $4,607.00 in company stock.

  • Percentage Held by Insiders

    21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Werewolf Therapeutics' insider trading history.
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HOWL Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
See More Headlines

HOWL Stock Analysis - Frequently Asked Questions

Werewolf Therapeutics' stock was trading at $1.48 at the beginning of the year. Since then, HOWL shares have decreased by 27.0% and is now trading at $1.08.
View the best growth stocks for 2025 here
.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. Werewolf Therapeutics had a negative net margin of 578.80% and a negative trailing twelve-month return on equity of 58.83%.

Werewolf Therapeutics (HOWL) raised $101 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Werewolf Therapeutics' top institutional shareholders include MPM Asset Management LLC (9.60%), MPM Bioimpact LLC (5.37%), Goldman Sachs Group Inc. (0.25%) and Charles Schwab Investment Management Inc. (0.21%). Insiders that own company stock include Ra Capital Management, LP, Luke Evnin and Bioventures 2014 LP Mpm.
View institutional ownership trends
.

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
5/08/2025
Today
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+675.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,370,000.00
Net Margins
-578.80%
Pretax Margin
-1,834.55%

Debt

Sales & Book Value

Annual Sales
$1.14 million
Price / Cash Flow
N/A
Book Value
$3.08 per share
Price / Book
0.35

Miscellaneous

Free Float
35,160,000
Market Cap
$48.24 million
Optionable
Optionable
Beta
0.48
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:HOWL) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners